cite
articl
mahdi
se
hassanian
ai
eldin
wmg
ibrahim
ee
fakhri
hm
valid
ultraviolet
new
inactiv
foot
mouth
diseas
viru
comparison
tradit
method
veterinari
world
aim
present
work
deal
differ
method
foot
mouth
diseas
viru
fmdv
inactiv
serotyp
opan
asia
heat
gamma
radiat
ultraviolet
uv
comparison
tradit
method
effect
antigen
virus
product
inactiv
vaccin
fmdv
type
opan
asia
propag
babi
hamster
kidney
titrat
divid
five
part
first
part
inactiv
heat
second
part
inactiv
gamma
radiat
third
part
inactiv
uv
light
fourth
part
inactiv
binari
ethylamin
last
part
inactiv
combin
binari
ethylamin
formaldehyd
beifa
evalu
method
inactiv
via
inocul
inocul
suckl
babi
mice
complement
fixat
test
formul
vaccin
use
differ
method
inactiv
appli
qualiti
control
test
evalu
formul
vaccin
effect
heat
gamma
radiat
uv
abil
replic
fmdv
opan
asia
determin
bhk
cell
line
passag
viru
aliquot
titer
tcid
strain
expos
min
similarli
anoth
aliquot
strain
contain
mm
depth
expos
sampl
petridish
expos
uv
light
nm
wavelength
one
foot
distanc
min
differ
dose
gamma
radiat
kgi
appli
dose
rate
gy
strain
repeat
time
dose
fmdv
opan
asia
inactiv
expos
heat
min
uv
inactiv
fmdv
opan
asia
obtain
within
min
min
type
ideal
dose
inactiv
fmdv
opan
asia
gamma
radiat
kgi
respect
inactiv
fmdv
binari
hr
opan
asia
respect
inactiv
beifa
determin
hr
opanasia
airan
respect
antigen
control
viru
inactiv
chang
inactiv
case
gamma
radiat
beifa
slightli
decreas
case
binari
declin
case
heat
uv
inactiv
respect
immun
respons
induc
inactiv
fmd
vaccin
gamma
radiat
beifa
last
month
postvaccin
binari
still
month
postvaccin
heat
uvinactiv
vaccin
effect
conclus
gamma
radiat
could
consid
good
new
inactiv
induc
result
inactiv
vaccin
binari
formaldehyd
beifa
foot
mouth
diseas
fmd
contagi
viral
diseas
affect
clovenhoof
anim
caus
highli
signific
loss
therefor
use
safer
high
potent
vaccin
requir
decreas
milk
product
weight
gain
reproduct
ineffici
death
young
rumin
main
econom
loss
caus
fmd
viru
inactiv
process
safeti
critic
step
product
fmd
vaccin
fmd
vaccin
particular
guarante
safeti
essenti
occurr
diseas
great
econom
consequ
fmd
vaccin
use
around
world
inactiv
vaccin
prophylact
emerg
use
gener
manufactur
basic
methodolog
outlin
oie
manual
inactiv
perform
use
chemic
physic
method
combin
two
wide
rang
wellestablish
novel
inactiv
method
describ
success
inactiv
virus
vaccin
purpos
exampl
formaldehyd
binari
ethyleneimin
bei
deriv
sodium
chlorid
phosphat
psoralen
hydrogen
peroxid
heat
avail
ultraviolet
uv
irradi
gamma
radiat
thermal
uv
irradi
inactiv
depend
function
dose
uv
depend
intens
time
uv
dose
defin
measur
incid
energi
absorb
energi
decim
inactiv
dose
defin
amount
uv
irradi
requir
minim
number
coloni
microorgan
factor
old
histori
fmd
vaccin
form
viru
inactiv
formalin
howev
main
disadvantag
formalin
alter
structur
virion
product
laboratori
chang
aziridin
group
inactiv
like
acetyl
ethylenamin
inactiv
inactiv
bei
use
particular
method
develop
circumv
direct
handl
toxic
aziridin
limit
studi
uv
inactiv
fmd
viru
fmdv
use
irradi
present
studi
design
investig
effect
heat
uv
foot
mouth
viru
strain
opan
asia
inactiv
addit
evalu
immun
respons
induc
prepar
vaccin
use
inactiv
comparison
tradit
prepar
bei
andor
formaldehyd
inactiv
vaccin
experi
per
protocol
institut
anim
ethic
committe
author
taken
permiss
anim
owner
privat
farm
babi
hamster
kidney
cell
line
bhk
obtain
world
refer
lab
pirbright
surrey
uk
cell
use
viru
propag
viru
titrat
well
confirm
complet
inactiv
process
fmdv
type
opan
asia
propag
monolay
cell
cultur
incub
hr
till
observ
morpholog
chang
cell
cytopath
effect
cpe
accord
declarq
et
al
longjam
et
al
viru
centrifug
rpm
min
supernat
separ
dispens
ml
glass
vial
store
till
use
serial
ten
fold
dilut
fmdv
prepar
tissu
cultur
plate
use
hank
solut
dilut
set
well
inocul
bhk
cell
control
noninfect
cell
inocul
hank
solut
plate
incub
day
observ
cytopath
chang
cpe
compar
control
noninfect
cell
final
titer
express
log
tcid
describ
reed
muench
bromoethylamin
hydrobromid
bea
obtain
aldrich
chemic
compani
limit
gillinham
dorest
uk
sodium
hydroxid
analar
naoh
molecular
weight
obtain
pratap
chemic
industri
pvt
ltd
india
use
concentr
normal
dissolv
bea
cycliz
process
accord
bahneman
formaldehyd
obtain
bdh
chemic
likit
pool
uk
molecular
weight
use
concentr
inactiv
process
accord
farid
et
al
sodium
thiosulf
na
molecular
weight
solut
doubl
distil
water
prepar
steril
autoclav
chemic
obtain
meck
compani
germani
use
final
concentr
neutral
excess
bea
inactiv
process
describ
bygirardn
et
al
sodium
bisulfit
na
molecular
weight
obtain
merck
compani
germani
prepar
solut
steril
autoclav
use
final
concentr
neutral
excess
formaldehyd
inactiv
process
accord
tofarid
et
al
fmdv
strain
opan
asia
viru
tcid
ml
subject
variou
temperatur
vari
time
viru
suspens
degre
temperatur
distribut
nine
tube
ml
capac
strain
contain
ml
viru
suspens
tube
expos
individu
sampl
tube
collect
min
interv
inactiv
gamma
irradi
dose
gamma
ray
kgi
use
irradi
viru
sampl
dose
rate
gy
irradi
done
artifici
ice
viru
suspens
dispers
steril
petridish
expos
uv
light
sourc
nm
viru
sampl
collect
min
interv
avail
inactiv
binari
bei
use
bei
bei
prepar
n
naoh
final
concentr
mm
bei
hr
ph
accord
bahneman
sodium
thiosulf
ad
treat
viru
inactiv
final
concentr
hr
neutral
effect
bei
inactiv
binari
formaldehyd
beifa
use
combin
bei
mm
fa
beifa
carri
accord
bartel
et
al
sodium
thiosulf
ad
viru
inactiv
final
concentr
h
also
sodium
bisulfit
ad
inactiv
neutral
rest
formaldehyd
cell
cultur
infect
inactiv
virus
differ
inactiv
studi
cell
cultur
method
sampl
inocul
cell
line
three
passag
viru
titer
determin
babysuckl
mice
inactiv
virus
inocul
suckl
mice
confirm
complet
inactiv
fmdv
albino
babysuckl
mice
day
inactiv
viru
sampl
inject
intraperitoni
read
record
th
day
postinocul
mice
still
aliv
mean
complet
viru
inactiv
death
indic
incomplet
inactiv
complement
fixat
test
cft
cft
done
accord
health
protect
agenc
test
antigen
antigen
use
vaccin
prepar
necessari
titrat
complement
know
minimum
hemolyt
dose
give
hemolysi
eppendorf
tube
contain
ml
complement
kept
dissolv
ml
veron
buffer
obtain
dilut
becam
dilut
made
give
dilut
correspond
dilut
ml
ad
well
cft
micropl
contain
ml
undilut
antigen
ml
veron
buffer
ml
hemolyt
system
hs
ad
one
control
well
contain
ml
veron
buffer
ml
hs
incorpor
plate
shaken
well
incub
min
plate
read
visual
lowest
percentag
complement
give
hemolysi
sheep
red
cell
consid
accur
complement
antigen
use
test
proper
ml
undilut
antigen
twofold
dilut
antigen
sampl
veron
buffer
ad
well
ml
refer
guinea
pig
hyperimmun
serum
ad
follow
ml
complement
two
well
use
control
first
one
receiv
ml
antigen
ml
complement
ml
veron
buffer
nd
one
receiv
ml
antigen
ml
veron
buffer
plate
incub
min
ml
hs
ad
well
follow
anoth
incub
min
posit
reaction
shown
hemolysi
well
vaccin
formul
carri
accord
method
describ
oie
oil
phase
consist
montanid
isa
mix
weight
inactiv
virus
weightweight
mix
thoroughli
vaccin
prepar
base
dose
ml
vaccin
contain
less
tcid
dose
antigen
pay
load
viru
type
thirti
calv
free
fmd
divid
six
group
five
calvesgroup
five
group
inocul
im
inactiv
prepar
vaccin
one
group
kept
control
without
vaccin
serum
sampl
obtain
group
vaccin
calv
everi
month
month
serum
sampl
examin
fmdv
strain
opan
asia
use
serum
neutral
test
snt
enzymelink
immunosorb
assay
elisa
test
perform
microtechniqu
describ
ferreira
estim
antibodi
fmd
sera
flat
bottom
tissu
cultur
microtit
plate
twofold
serial
dilut
sera
modifi
eagl
medium
use
dilut
per
well
distribut
well
viru
ad
tcid
ml
neutral
allow
occur
h
bhk
cell
ad
per
well
test
includ
normal
cultur
serum
viru
control
incub
hr
daili
microscop
examin
sn
titer
express
log
final
serum
dilut
protect
well
calcul
reed
muench
stain
snt
micropl
use
test
follow
procedur
appli
media
discard
cell
cultur
stain
crystal
violet
stain
min
excess
stain
discard
plate
wash
distil
water
least
time
left
min
dri
incub
done
accord
hamblin
et
al
determin
fmd
antibodi
sera
vaccin
sheep
follow
prepar
elisa
antigen
fmdv
type
opan
asia
propag
bhk
clone
cultur
cpe
observ
infect
cell
cultur
frozen
thaw
three
time
releas
fmdv
extracellular
viru
suspens
centrifug
rpm
cool
centrifug
min
supernat
collect
concentr
polyethylen
glycol
titer
conjug
elisa
microtit
plate
coat
coat
buffer
well
plate
incub
overnight
wash
wash
buffer
least
time
plate
block
phosphat
buffer
salin
pb
bovin
albumin
incub
overnight
serial
dilut
conjug
rabbit
antibovin
immunoglobulin
g
horseradish
peroxidas
label
made
dilut
buffer
pb
bovin
albumin
amount
dilut
place
vertic
column
well
flatbottom
micropl
mean
micropipett
work
solut
orthophenylen
diamin
opd
substrat
freshli
prepar
ad
well
plate
cover
place
shaker
slow
speed
rotatemin
dark
place
reaction
stop
ad
sulphor
acid
mol
well
plate
read
elisa
reader
wavelength
nm
end
point
dilut
optic
densiti
od
titer
conjug
antigen
titrat
determin
optimum
concentr
antigen
use
assay
determin
checkerboard
method
titrat
dilut
antigen
ran
posit
neg
sera
serial
dilut
fmd
antigen
viru
strain
made
use
coat
buffer
solut
dilut
transfer
two
success
horizont
column
plate
plate
cover
incub
overnight
sensit
plate
forc
decant
wash
five
time
wash
buffer
pb
tween
dri
tap
upsid
filter
paper
clean
tube
serial
twofold
dilut
posit
neg
control
sera
made
use
pb
bovin
albumin
dilut
buffer
start
first
vertic
two
row
left
blank
per
well
strong
serum
dilut
transfer
horizont
row
number
correspond
antigen
dilut
respect
last
horizont
row
h
receiv
per
well
neg
control
serum
plate
incub
h
content
decant
plate
wash
time
dri
dilut
conjug
solut
previous
titrat
ad
well
plate
reincub
hr
decant
wash
dri
freshli
prepar
substrat
opd
ad
well
plate
cover
shake
shaker
slow
speed
min
dark
place
reaction
stop
ad
stop
solut
mol
sulphor
acid
well
plate
read
use
elisa
reader
wavelength
nm
highest
dilut
viru
antigen
gave
od
posit
control
serum
use
test
proper
test
proper
sera
collect
experiment
inocul
sheep
test
fmd
antibodi
use
elisa
techniqu
coat
elisa
plate
coat
fmd
antigen
ad
dilut
antigen
carbonatebicarbon
buffer
accord
titer
flatbottom
well
plate
incub
overnight
plate
content
decant
plate
wash
three
time
wash
buffer
dri
describ
block
coat
plate
block
ad
block
buffer
pb
buffer
serum
bovin
albumin
per
well
incub
overnight
content
decant
plate
wash
dri
serum
dilut
well
coat
plate
ad
ml
test
serum
ad
first
well
make
final
dilut
serum
sampl
run
duplic
includ
control
posit
strong
weak
posit
sera
neg
sera
well
blank
control
plate
cover
incub
h
addit
conjug
content
plate
decant
wash
three
time
use
wash
buffer
dilut
conjug
ad
well
plate
cover
incub
h
addit
substrat
content
plate
decant
wash
time
wash
buffer
solut
substrat
opd
ad
well
plate
cover
incub
dark
place
min
brownish
color
indic
posit
reaction
develop
addit
stop
solut
reaction
stop
ad
per
well
mol
sulphor
acid
plate
read
use
elisa
reader
nm
interpret
result
mean
od
sampl
control
inactiv
agent
includ
temperatur
uv
show
variabl
effect
surviv
fmd
opan
asia
viru
effect
temperatur
vitro
replic
fmdv
repres
viru
suspens
expos
heat
treatment
inactiv
min
exposur
show
cpe
bhk
cell
line
howev
viru
suspens
expos
heat
treatment
got
inactiv
min
interact
time
result
show
complet
inactiv
done
exposur
temperatur
min
effect
uv
treatment
surviv
viru
shown
tabl
cpe
observ
viru
neg
control
well
l
well
viru
inactiv
sampl
signific
cpe
note
posit
control
viru
demonstr
antigen
control
viru
inactiv
antigen
chang
inactiv
case
gamma
radiat
binari
formaldehyd
slightli
decreas
demonstr
immun
respons
inactiv
fmd
vaccin
gamma
radiat
binari
formaldehyd
last
month
postvaccin
binari
bei
still
month
postvaccin
mpv
heat
uv
inactiv
vaccin
effect
inactiv
method
fmdv
includ
use
formaldehyd
ethyleneimin
propylen
imin
agent
residu
final
product
toxic
caus
allerg
respons
anim
research
studi
inactiv
fmd
viru
strain
use
differ
method
temperatur
treatment
fmdv
min
undetect
effect
fmdv
serotyp
pan
asia
result
came
parallel
mention
razdan
et
al
record
infect
titer
fmd
viru
mainten
cell
cultur
medium
reduc
log
unit
storag
h
indic
viru
temperatur
interact
time
invers
effect
viru
infect
heat
treatment
period
min
longer
time
suitabl
complet
inactiv
viru
heat
treatment
inactiv
fmd
viru
heat
viru
suspens
min
reduc
infect
high
temperatur
may
done
destruct
viru
receptor
ultim
declin
infect
c
serotyp
fmd
viru
may
inactiv
h
uv
light
effect
viru
interact
time
min
viru
produc
cpe
bhk
cell
line
inactiv
fmdv
opan
asia
occur
within
min
min
type
find
align
nuanualsuwan
et
al
rabia
et
al
observ
vesicular
stomat
fmdv
inactiv
expos
uv
light
sourc
find
align
hazem
mention
viru
resist
properti
uv
light
ideal
dose
inactiv
fmdv
gamma
ray
obtain
kgi
accord
viru
strain
complet
inactiv
determin
kgi
fmdv
kgi
fmdv
kgi
fmdv
result
agreement
sedehl
et
al
record
ideal
dose
rang
gamma
ray
fmd
viru
inactiv
viru
titrat
tcid
ml
obtain
kgi
furthermor
result
safeti
test
irradi
sampl
gamma
ray
dose
suitabl
detect
cpe
three
time
cell
cultur
inactiv
viru
bei
show
complet
inactiv
fmdv
opan
asia
within
hr
respect
inactiv
viru
use
combin
bei
formaldehyd
condit
show
complet
inactiv
fmdv
opan
asia
within
hr
respect
result
agre
ali
et
al
mention
inactiv
bei
concentr
fmd
type
viru
complet
inactiv
h
fmdv
type
complet
inactiv
h
furthermor
agre
bahneman
aarthi
et
al
ismail
et
al
whose
show
complet
inactiv
fmdv
type
residu
viru
detect
antigen
control
viru
inactiv
inactiv
virus
gamma
radiat
binari
formaldehyd
reduc
use
bei
alon
declin
heat
uv
inactiv
respect
result
agre
mention
cf
content
inactiv
viru
type
bei
reduc
inactiv
also
chang
antigen
combin
beiformaldehyd
viru
type
result
agre
avail
bahneman
mention
complement
fixat
type
viru
use
beiformaldehyd
inactiv
chang
inactiv
process
come
agreement
result
obtain
ali
et
al
inactiv
virus
show
residu
viabl
viru
detect
tissu
cultur
babi
mice
therefor
inactiv
viru
could
antigen
good
safeti
test
result
prepar
inactiv
vaccin
formul
vaccin
inocul
anim
studi
anim
immun
seronutr
elisa
method
immun
respons
inactiv
fmd
vaccin
gamma
radiat
binari
formaldehyd
last
month
postvaccin
binari
bei
still
mpv
heat
uvinactiv
vaccin
effect
result
agreement
ljungman
et
al
record
improv
safeti
vaccin
suitabl
rapidli
increas
immunocompromis
final
conclud
gamma
radiat
could
consid
good
new
inactiv
induc
immun
respons
inactiv
vaccin
binari
formaldehyd
sem
inocul
cell
cultur
fmdv
serotyp
share
titer
inactiv
process
differ
method
aih
inocul
cell
cultur
fmdv
serotyp
opan
asia
share
titrat
inactiv
process
differ
method
opan
asia
wmge
inocul
cell
cultur
fmdv
serotyp
share
titer
inactiv
process
differ
method
eei
prepar
clone
viru
inocul
titrat
snt
also
share
inactiv
process
differ
method
write
manuscript
followup
step
public
hmf
share
inactiv
process
differ
method
confirm
complet
inactiv
process
differ
method
measur
antigen
content
appli
snt
elisa
write
manuscript
